Rift Valley fever: surveillance measures assessed

Written by Embio Diagnostics

November 4, 2020

EFSA has completed its series of assessments on Rift Valley fever (RVF) with a scientific opinion looking at the effectiveness of surveillance and control measures in the EU.

The latest opinion follows two opinions published earlier this year which assessed respectively the risk of introduction of RVF to the EU and the impact of the disease in the French overseas department of Mayotte.

Background

Rift Valley fever is a vector-borne disease transmitted by mosquitoes to animals – domestic and wild ruminants and camels – and humans.

The disease is endemic in sub-Saharan Africa and in the Arabian Peninsula, but has never been reported in continental Europe although its range is expanding. In 2018-19 it reappeared after ten years in Mayotte, where there have been outbreaks involving multiple human cases.

https://www.efsa.europa.eu/en/news/rift-valley-fever-surveillance-measures-assessed

You May Also Like…

About Us.

EMBIO Diagnostics (EMBIO) designs and develops custom based hardware solutions and consults as an expert in the biotechnology at a global scale.

Follow the developments.

 

Contact us

Get In Touch

Cyprus

(+357) 22515175
info@embiodiagnostics.eu
M-F: 9am-6pm

Athalassas Avenue 8B,2018, NIcosia

USA

(+001) 973 876 1792

sales@embiodiagnostics.eu